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INTRODUCTION
The pharmaceutical industry creates and de-
velops new or approved therapeutic agents and con-
sumables, aiming to meet the unsatisfied needs of 
their customers. It is one of the largest and most dy-
namically developing industries. 3.2 billion euro 
(IMS Health) were spent on healthcare in Bulgaria in 
2013. Considering the past 2-3 years we can speak of 
relative stability or changes with slight influence. In 
Bulgaria treatment of BPH with medications made 
its way in 1995 and in the first years the market bare-
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The aim of this article is to analyse the market of prescription medications for benign prostatic hyperplasia 
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for the past two years. Almost all participants in the market show development in number of sold packag-
es/boxes.
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ly reached 200 000 BGN per year. During that peri-
od only original Tamsulosin was marketed (from the 
end of 1997), Doxazisin (from the middle of 1997), 
Finasterid (from the beginning of 1995), hormon-
al therapy and 1-2 phytotherapy products. Prices of 
medicines were comparable in the absence of or very 
low reimbursements then provided by municipali-
ties. Broadly speaking, the reasons for the low market 
share at that time were both doctors’ attitudes and 
lack of experience, as well as the low level of patients’ 
awareness.  In the course of time and after the pat-
ents expired, lots of new original and generic medi-
cines appeared on the market.
MATERIALS AND METHODS
Analysis of documents and published sources; 
comparative analysis of data on prescription med-
icines for benign prostatic hyperplasia from IMS 
Health.
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RESULTS AND DISCUSSION 
A number of factors have an impact on the de-
velopment of the pharmaceutical market in Bulgar-
ia. They have been very dynamic for a particular pe-
riod of time, which has challenged market devel-
opment forecasts. A major competitor of treatment 
with medications has been the surgical approach, as 
according to many medical textbooks, TURP (trans-
urethral resection of the prostate) has been a “gold 
standard” approach for BPH. The changes in prices 
of medicines, as well as the changes in the attitudes of 
doctors, the prescribing practices, and the process of 
reimbursement also had an impact. With the launch 
of the reimbursement system in June 2000 and the 
TV commercials of phytotherapy products for the 
treatment of BPH the market changed drastically.  
The main groups of medicines for the treatment 
of BPH are:
 ❖ Original Tamsulosin;
 ❖ Generic Tamsulosin;
 ❖ Other α-blockers (selective and non-selective, 
original and generic); 
 ❖ 5 α-reductase Inhibitors;
 ❖ Combination Drugs;
 ❖ Phytotherapeutic products and food 
supplements.
The pharmaceutical companies marketing 
medicines for the treatment of BPH have different 
portfolios. Some of them offer two or more products. 
The largest group is the one of plant extracts from 
which only a small part is marketed by doctors, and 
the majority relies on advertising. 
Each of the companies struggles for a market 
share and the maintaining of positions is primari-
ly a matter of product price. This approach is typical 
for producers of generics and as a whole has a posi-
tive effect on the market since the majority of the pa-
tients are able to afford the treatment. Products with 
the active ingredient tamsulosin represent the largest 
market share of prescription products. They are the 
most numerous and competition is chiefly among 
themselves. Some of the manufacturers change prod-
uct prices several times a year, thus producing a dou-
ble effect: firstly, they reach the lowest price within 
their class and secondly, they become a point of refer-
ence for other Tamsulosins. No such tendency is ob-
served for the group of the plant extracts. 
The pharmaceutical market is extremely spe-
cific mostly because it is subject to serious regula-
tions. Two are the basic market regulators – the Na-
tional Health Insurance Fund and the Association of 
the Research-Based Pharmaceutical Manufacturers 
in Bulgaria (ARPharM) through the Code of Ethics. 
The first regulator determines the way and rules of 
reimbursement which have been seriously changed 
in the course of the years. That makes correct fore-
casting of the market development of a particular 
product very difficult. 
Initially the reimbursement for BPH medicines 
was 25% of its own price i.e. each product was its own 
point of reference. Later it has been changed to 50% 
of the price of the cheapest generic product which is 
highly unfavourable for medicines with higher price. 
The period for filing applications for reimbursement 
has also been changed – from no specific time period 
to twice a year and since June 2014 – once a year. This 
means that the manufacturer has to wait until the 1st 
January to get a reimbursement. The second regula-
tor, which concerns only brand-name companies, is 
the Association of the Research-Based Pharmaceuti-
cal Manufacturers in Bulgaria (ARPharM). Through 
annual changes in the Code of Ethics it constantly 
limits the activities of its members. The majority of 
the restrictions are in the right direction. This how-
ever, creates inequality between the brand-name and 
generic pharmaceutical companies and affects their 
relationships with clients who, on the other hand, do 
not distinguish between them.
Product/Year 2012 2013 2012 2013
Total Market 1259008 1469678 Market Share Market Share
Original Tamsulosin 0,4 mg 136828 172781 10.87% 11.76%
Generics 437868 480118 34.78% 32.67%
Table 1. Market development of prescription products for treatment of BPH by number of packages/boxes and market 
share
Source: IMS Health
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There is a huge diversity on the Bulgarian mar-
ket of products for the treatment of BPH, the pre-
scription products being more than 20 and phyto-
therapy ones about the same number. Despite that 
the market is constantly growing and new products 
are being offered.
This analysis covers a period of two years – 2012 
and 2013, since in 2012 the price of the original Tam-
sulosin 0.4 mg was reduced by 35% and it is pointless 
to include a longer past period. Part of the α-blockers 
(Doxazosin) are used for treatment of arterial hyper-
tension but it is considered that the number of pack-
ages sold for that indication is a negligible amount, 
bearing in mind the rating of this class of medicines 
in the therapeutic approach towards this disease. 
In comparison with the prices of ethical phar-
maceutical products for treatment of BPH we will re-
view the dynamics of the market in the past 2 years 
in packages/boxes and money.
Figure 1 indicates that although the market of 
prescription products for the treatment of BPH is 
saturated, it continues to grow with a preference for 
lower-price generics. 
Presented data shows market growth. Combi-
nation drugs are the key market driver.  The reduc-
tion in the price of the majority of Tamsulosins as 
well as that of the original Tamsulosin 0.4 mg leads 
to a reduction in their market share in terms of mon-
ey. The increased sales in packages/boxes are small-
er in percentages than the price reduction of original 
Tamsulosin 0.4 mg in percentages which determines 
the decline in sales in terms of money. The data in-
dicates that preferences are for the cheapest generics. 
There is a clear tendency for shrinking of the 
market share in money of the original Tamsulosin 
0.4 mg, the generic Tamsulosins and an increase in 
the market share of the combination drugs.
Table 3 shows a clearly expressed tendency to-
wards reduction of the market share in terms of days 
of treatment for generic Tamsulosins. The tendency 
Fig. 1. Market development of prescription products for 
treatment of BPH in packages/boxes
Source: IMS Health
Product\Year 2012 2013 2012 2013
Total Market 12097961 13069282 Market Share Market Share
Original Tamsulosin 1936237 1633911 16.00% 12.50%
Generic Tamsulosins 3016170 2578353 24.93% 19.73%
Combination Drugs 3530725 4688797 29.18% 35.88%
Table 2 .Development of the market of prescription products for treatment of BPH in money (Euro)/market share
Source: IMS Health
Fig. 2. Market development of prescription products for 
treatment of BPH in money (Euro)
Source: IMS Health
Product\Year 2012 2013
Total market 100% 100%
Original Tamsulosin 11.94% 12.89%
Generic Tamsulosins 36.33% 32.96%
Source: IMS Health
Table 3. Development of the market of prescription prod-
ucts for treatment of BPH in days of treatment (DOT)
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is for growth in the market share in terms of days of 
treatment with original Tamsulosin 0.4 mg.
CONCLUSIONS
Due to the specific nature of its production the 
pharmaceutical industry is one of the most regulat-
ed manufacturing activities in countries with devel-
oped market economy. This is the main reason why 
state authorities, namely the Ministry of Finance, 
the Ministry of Healthcare, the National Health In-
surance Fund and municipalities play a determin-
ing role in the marketing of pharmaceutical products 
(the so called “institutional users”). 
The market of medicines for the treatment of 
BPH keeps growing. Almost all participants in the 
market show development in the number of sold 
packages/boxes – the increase for the original Tam-
sulosin 0.4 mg is 38% which surpasses the develop-
ment speed of the total market, which is 31%.
The market of medicinal products for the treat-
ment of BPH is not an exception from the general 
pharmaceutical market. Although not so dynamic as 
it was a few years ago, it continues to provoke inter-
est and new manufactures and/or molecules (main-
ly generic ones) keep appearing. The market analy-
sis shows that Tamsulosin 0.4 mg is still the market 
leader for BPH treatment.
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